Aribio Lab

AriBio Lab (formerly known as CHA Vaccine Institute) is a clinical-stage South Korean biotechnology company specializing in the development of next-generation vaccines and immunotherapies. The company leverages its proprietary immune-enhancing platform technologies, L-pampo™ and Lipo-pam™, which act as powerful adjuvants to stimulate Toll-like receptors (TLR2 and TLR3) and boost vaccine efficacy. Its clinical pipeline includes CVI-VZV-001, a recombinant shingles vaccine currently in Phase 2 trials, and CVI-HBV-002, a therapeutic and prophylactic hepatitis B vaccine candidate. Following its integration into the AriBio Group in 2026, AriBio Lab is also collaborating with its parent affiliates to develop a novel Alzheimer's disease prevention vaccine.